IL6 and cancer: Rg3-PTX-LPs remodeled the immunosuppressive microenvironment by inhibiting the activation of IL-6/STAT3/p-STAT3 pathway, reduced the number of MDSCs, promoted tumor cell apoptosis, and increased the cancer suppression rate 43.